Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivoceranib in Recurrent or Metastatic Adenoid Cystic Carcinoma
NCT04119453Phase 2Terminated
- Sponsor
- Elevar Therapeutics
- Start
- Jan 2020
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of Rivoceranib in adenoid cystic carcinoma (ACC), sponsored by Elevar Therapeutics. Started Jan 2020; status: terminated.
02
Drugs
Rivoceranib
03
Conditions
adenoid cystic carcinoma (ACC)
Beyond the preview
Go deeper on NCT04119453.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04119453.